A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489 (NCT07073820)
A PHASE 2, OPEN-LABEL EXTENSION STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF PF-07868489 ADMINISTERED TO ADULT PARTICIPANTS WITH PULMONARY ARTERIAL HYPERTENSION
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to learn about the long-term safety, tolerability and effects of the study medicine (PF-07868489) for the possible treatment of PAH. PAH is a condition in which there is high blood pressure in the arteries that carry blood from the heart to the lungs. This high pressure makes it harder for the heart to pump blood through those lungs, potentially damaging the right side of the heart. This is an open-label study. Which means that both the healthcare providers and the study participants are aware of the medicine being given. This study is also an extension study with study medicine (PF-07868489). An extension study allows patients from an earlier clinical study (also called as qualifying study) to continue participating to assess long-term benefits and safety of the medicine.
Who can join: Review the eligibility criteria below.
Location: UCSF Health St. Mary's Hospital — San Francisco, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (27 Sites)
Showing the first 25 of 27 sites.
- UCSF Health St. Mary's Hospital — San Francisco, California
- Heart and Vascular Center — San Francisco, California
- UCSF Helen Diller Medical Center at Parnassus Heights — San Francisco, California
- Mount Sinai Hospital — New York, New York
- Royal Prince Alfred Hospital — Camperdown, New South Wales
- Pulmonary Hypertension Research Queensland Pty Ltd — Auchenflower, Queensland
- HUB Hôpital Erasme — Brussels,
- UZ Leuven — Leuven,
- Guangdong Provincial People's Hospital — Guangzhou, Guangdong
- The Second Xiangya Hospital of Central South University — Changsha, Hunan
- Zhongda Hospital Southeast University — Nanjing, Jiangsu
- Shanghai Pulmonary Hospital — Shanghai, Shanghai Municipality
- Vseobecna fakultni nemocnice v Praze — Prague,
- Thoraxklinik-Heidelberg gGmbH — Heidelberg, Baden-Wurttemberg
- Universitätsklinikum Regensburg — Regensburg, Bavaria
- Universitaetsklinikum Giessen und Marburg GmbH — Giessen, Hesse
- Universitätsmedizin Greifswald — Greifswald, Mecklenburg-Vorpommern
- Universitaetsklinikum Carl Gustav Carus, Technischen Universitaet Dresden — Dresden, Saxony
- Kobe University Hospital — Kobe, Hyōgo
- St. Marianna University Hospital — Kawasaki, Kanagawa
- National Hospital Organization Okayama Medical Center — Okayama,
- Gachon University Gil Medical Center — Incheon, Incheon-gwangyeoksi [incheon]
- Seoul National University Hospital — Seoul, Seoul-teukbyeolsi [seoul]
- Severance Hospital, Yonsei University Health System — Seoul, Seoul-teukbyeolsi [seoul]
- Samsung Medical Center — Seoul, Seoul-teukbyeolsi [seoul]
📞 Contact the Study Coordinator
Phone: (877) 827-3222
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Pulmonary Hypertension
- Trans-pulmonary Biomarkers in Pulmonary Hypertension — Nashville, Tennessee
- Activity Monitoring in Pulmonary Hypertension — Nashville, Tennessee
- LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF — Tucson, Arizona
- A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study) — Phoenix, Arizona
- A Study of Mosliciguat in PH-ILD — Phoenix, Arizona
- Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPD — San Francisco, California
Explore by condition: All Pulmonary Hypertension clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.